Overview
This study evaluated the lymphocyte transformation test (LTT) and in vitro cytokine release to differentiate true palladium monosensitization from nickel-palladium cross-reactivity in patch-test-positive patients. Using data from both a clinical sample (n=13) and the German DKG registry (n=1017), the work characterizes the proportion of Pd-positive patients who are independently sensitized vs cross-reactive with nickel (Ni).
Key numbers
- 13 Pd patch-test-positive patients recruited from 70 screened
- DKG registry 2006-2016: 1017 Pd-positive individuals
- 782 of 1017 (76.9%) also reacted to Ni
- Approximately 235 (23.1%) monosensitized to Pd (DKG registry)
- Patients with concomitant Ni reaction: lymphocyte proliferation at lower Pd concentrations (less than 3.13 x 10^-5 M)
- LTT differentiates independent sensitization from cross-reactive pattern
Methods (brief)
Clinical recruitment of Pd patch-test-positive patients. Lymphocyte transformation test (LTT) with Pd at graded concentrations. In vitro cytokine release assay (IFN-gamma, IL-5) for Pd and Ni stimulation. DKG (Deutsche Kontaktallergie-Gruppe) registry data reviewed for population-level co-sensitization rates (2006-2016).
Implications
This page makes the source discoverable for palladium evidence routing. Provides both population-level (DKG registry) and clinical (LTT) data on Pd monosensitization vs Ni/Pd cross-reactivity, with the finding that LTT can distinguish these two patterns, which is clinically important for guiding dental material selection in Pd-allergic patients.
Related evidence
Update history
No substantive edit history is available in this build. The full commit record is available in git.